Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review

Autor: Young, Guy, Pipe, Steven W., Kenet, Gili, Oldenburg, Johannes, Safavi, Mariam, Czirok, Tuende, Nissen, Francis, Mahlangu, Johnny
Zdroj: In Research and Practice in Thrombosis and Haemostasis May 2024 8(4)
Databáze: ScienceDirect
Externí odkaz: